iiinova — where your digital self keeps evolving

Michael D. Green, PhD @michaeldgreen.phd · 6h

One of the most striking things from an essay in @theatlantic.com from an employee at OpenAI who resigned last week. Empathy and humility are absent from so many these days. Really appreciate this message. www.theatlantic.com/technology/2...

The future depends on wisdom that Silicon Valley lacks. Wisdom about how to handle dangerous technology and, more
fundamentally, wisdom about what it means to care for people. This moment needs a degree of humility that isn't natural for people who have succeeded through their extreme confidence.
My former colleagues at

182

Michael D. Green, PhD @michaeldgreen.phd · 02/10/2026

I appeared alongside the CEO of @aaas.org on the WSITY podcast, where we spoke about the future of science. Politics currently undermine that future in ways that many will not immediately see, but the long-term results will be devastating if we don’t change course and demand more.

Maggie Bartlett -- WSITY
Brinda Adhikari -- WSITY
Tom W. Johnson -- WSITY
NURE
Dr. Mark Abdelmalek -- WSITY
Michael D. Green (He/Him)
Sudio Parikhi

Special Ep: Who Gets to Decide What Science Gets Funded? Inside the Fight Over NIH: A Conversation w Sudip Parikh & Michael Green

1133

Michael D. Green, PhD @michaeldgreen.phd · 02/10/2026

Gr8 chart here from @jaspar.bsky.social of @statnews.com Thankfully for NIH awards, it’s possible to evaluate claims like “we want to support early-career scientists” with data. The data does not support that claim.

A chart that shows that funding early career scientists have plateaus

Early-career grant funding has plateaued since 2024
Value of early-career project grants awarded in 2026 vs. previous years
1.85B1.918
1.5B
1.48B
1.5587.62฿
1.7B 1.74B
1.98P1.94E1.91B
1B
500M
2018
2020
2022
2024
2026
Early-career grants included activity codes F30, F32, T32, T43, T35, TL1, K01, K08, K12, K22, K23, K24, K43, K99, and ROO.
Chart: J. Emory Parker/STAT • Source: STAT Analysis of NIH RePORTER

13212

Michael D. Green, PhD @michaeldgreen.phd · 30/09/2026

Meanwhile most people I know are more worried about access, not “tyranny”

Meme with a skinny guy that says healthcare pls

061

Michael D. Green, PhD @michaeldgreen.phd · 29/09/2026

Man what do yall got going on over on the West coast??

Some of their disputes were related to business and strategy decisions, but others seemed more like ethical lapses to Amodei.
Altman, for example, had met Kanye West and offered to let him into the GPT-3 private beta in 2020, according to two people familiar with the offer. Jack Clark, OpenAl's policy director, quashed the idea, pointing out that West had recently posted a video that seemed to show himself urinating on a Grammy award and appeared to be mentally unstable. (This was before the period in which West began to publicly express admiration for Hitler.)

1126

Michael D. Green, PhD @michaeldgreen.phd · 28/09/2026

are patients going to see enough positive benefits from layering this stuff on a broken system? Are the increased costs worth the results? www.notbeinggreen.com/p/curing-all...

are patients going to see enough positive benefits from layering this stuff on a broken system? Are the increased costs worth the results?

https://open.substack.com/pub/notbeinggreen/p/curing-all-diseases-does-not-mean?r

050

Michael D. Green, PhD @michaeldgreen.phd · 28/09/2026

Study from Blue Cross Blue Shield indicates that using AI is increasing billing for hospital systems. Most of those costs are coming from increased secondary diagnosis. Costs going up for patients and consumers, not exactly what people were looking for! www.bcbs.com/about-us/ass...

BlueCross BlueShield
Analysis examines Al in hospital billing as spike in complex patients adds nearly $1 billion in extra costs
SEPTEMBER 24, 2026

160

Michael D. Green, PhD @michaeldgreen.phd · 21/09/2026

Hmmm so now the WH (known truth tellers) are saying this dispute did not happen, and JB + NIH folks don’t have comments to provide. When there’s smoke there’s fire!

A White House official has denied the reports of a blow-up in the Oval Office as
"baseless speculation."

"The Trump administration remains committed to the core mission of the NIH," the official said in an unsigned statement.
Neither Bhattacharya nor NIH responded to requests for comment from STAT.

284

Michael D. Green, PhD @michaeldgreen.phd · 20/09/2026

Some interesting notes in this new @nytimes.com article on alleged plans for OMB to take control of NIH grants… (gift link) www.nytimes.com/2026/09/20/s...

Their relationship has grown so contentious that Mr. Vought had refused to meet with Dr.
Bhattacharya, the people said. During the session on Friday, Mr. Vought accused the N.I.H. director of funding projects that were in conflict with administration priorities, such as supporting research related to diversity and equity.

Traditionally, the N.I.H. selects projects based on expert review of their scientific merit. But Mr. Trump has sought through a series of recent directives in his second term to bring that process under political review, arguing in part that the government has been funding "woke" liberal priorities.
Friday's meeting brought to a head months of conflict between two of the attendees: Mr.
Vought of the O.M.B., who wants to impose greater political control over N.I.H. grant approvals, and Dr. Jay Bhattacharya, the N.I.H. director, who is resisting those efforts, according to two people close to Dr.
Bhattacharya.
ADVERTISEMENT

122

Michael D. Green, PhD @michaeldgreen.phd · 17/09/2026

Also outlined this sentiment when @aniloza.bsky.social interviewed me for his @statnews.com story covering this. www.statnews.com/2026/09/16/l...

To Green, if he and others don't prevail in the suit, "the bottom falls out from under the NIH," he said in an interview. "To this day, I didn't get clarity on why my work was targeted."
That opacity has made it difficult to trust the agency right now, he said. As a result, what he sees as the main draw of academia -
being able to openly ask questions to better understand the world - feels tenuous. For now, that has meant he's also stopped applying for NIH grants.

49510

Michael D. Green, PhD @michaeldgreen.phd · 05/09/2026

A librarian and 1 center that thinks about AI-centric stuff don’t outweigh how much whack a mole people are doing navigating AI-slop. I’m also still waiting for evidence that “AI-training” is a real thing. All the people I know who use AI in a way I respect were already very savvy at baseline.

Practice using Al matters even more when students start to specialize. To help prepare business students for Al use in the real world, Dartmouth's Tuck School of Business now requires that they use the technology to build and test solutions for clients in their First-Year Project. Thanks to this experience, students who lacked AI expertise when they entered the program reported greater confidence using the technology by the end of their first year. At Dartmouth's Geisel School of Medicine, our faculty developed an Al Patient Actor to help medical-school students sharpen their communication and interpersonal skills with the benefit of realtime feedback. The tool is now being used by more than 100 medical institutions worldwide.

Harnessing AI ethically and productively requires understanding what the technology is and where it falls short. This is why Dartmouth, along with other schools such as Johns Hopkins University and Rollins College, has employed a critical Al librarian, an educator who helps students and faculty interrogate these models, recognize their biases, and spot unsupported claims. At our DALI Lab, where students design and create technological products, they can now build and stress-test their own Al models, which elevates their understanding of the risks and rewards at play. Our ambition at Dartmouth is for every undergraduate to experience a team-based AI project that relates to their coursework by the time they graduate.

Globally, jobs that require advanced Al skills are growing eight times faster than the job market overall, according to an analysis from the professional-services network PC. At the same time, entry-level roles in Al-exposed fields are more than seven times likelier than other entry-level jobs to require the human skills once reserved for senior executives, including discernment, creativity, and leadership. Never before has the ability to harmonize critical thinking and technology mattered more for graduates.
There will not—and should not—be a one-size-fits-all solution to the challenges of supplying this education. One professor may decide that students should write their essays in a blue book in class, while another may ask them to use an Al tool and audit every step of this work. Both choices will serve students

181

Michael D. Green, PhD @michaeldgreen.phd · 25/08/2026

At a conference 2 yrs ago I presented some of my work on reporting of race and ethnicity for clinical trials. A prof told me that he doesn’t think my research is worth pursuing b/c reporting doesn’t matter. Here’s a JAMA IM editorial explaining why it does. jamanetwork.com/journals/jam...

At JAMA Internal Medicine, we have become increasingly aware that some US researchers are unable to report on race or ethnicity as demographic variables to describe their sample or to conduct stratified analyses by these variables. In some cases, we have been informed that based on 3 recent US federal executive orders, -3 the stewards of federal databases, such as those responsible for distributing data from the Centers for Medicaid and Medicare Services (CMS), are unable to release any race or ethnicity data for research purposes. The restrictions may be particularly prohibitive when study investigators are US federal employees. We have been informed of similar concerns occurring at other biomedical journals. The potential for restricted access to race and ethnicity data across many federal databases has been high-lighted, 4 with disruptions reported during 2025 at the Behavioral Risk Factor Surveillance System (BRFSS) and other Centers for Disease Control and Prevention (CDC) databases, the US Census database, Health and Human Services (HHS), and National Institutes of Health (NIH) public use databases.

It follows that the nonreporting of race or ethnicity in biomedical publishing can limit the in-terpretation, reproducibility, and applicability of research findings. Without information on participants' racial or ethnic backgrounds, it is difficult to assess whether study results are generalizable across diverse populations or whether important differences in disease risk, treatment response, and health outcomes exist among subgroups." For example, disaggregating mortality data on Asian American and Pacific Islander individuals showed higher all-cause and cause-specific mortality rates among Pacific Islander adults that would not have been apparent if the data were not reported.'2 Another example is a recent review highlighting the disproportionate impact of metabolic dysfunction-associated steatotic liver disease on the Hispanic or Latino population. '3 The authors emphasize the need for disaggregating this larger group to capture the cultural nuances of specific groups to best apply effective treatment strategies.
This lack of reporting may also obscure health disparities, hinder efforts to address inequities, and reduce the ability of clinicians and investigators to develop or evaluate evidence-based interventions that will be effective across all populations. Moreover, nonreporting of race or ethnicity will preclude the ability to conduct meta-analyses or data syntheses that combine results by racial or ethnic subgroups across multiple studies or trials. Such analyses have been critical to generate adequate power to uncover therapeutic differences across racial and ethnic subgroups and to understand specific mechanisms to improve treatments that may be more effective across all populations. One example is the discovery of variation in the effectiveness of clopidogrel and proton pump inhibitors among some Southeast Asian populations, which was based on meta-analyses of genetic variants. 4 Generalizability to all subgroups is crucial because these meta-analyses o…

Thus, transparent and consistent reporting of race and ethnicity is essential for continued scientific progress that benefits all of us. Understanding effects and outcomes across racial and ethnic subgroups is important for improving scientific rigor, promoting health equity, and ensuring that biomedical research benefits all. Calling out the serious adverse consequences and implications of these executive orders on medical progress is our responsibility as medical editors and health care professionals.

2175

Michael D. Green, PhD @michaeldgreen.phd · 23/08/2026

This right here. Institutions are not immune from critique. DEI programs should be critiqued, especially if they are not yielding results. Talk to the (few) Black faculty about the root of issues in academia and they will not talk about “meritocracy”. They will talk about systems and dual standards

Elite academia was never a pristine meritocracy that diversity initiatives suddenly corrupted.
It still isn't. I'll tell you stories the next time you see me.
Universities have always distributed opportunity through pedigree, patronage, elite networks, recommendation letters, disciplinary fashions, social capital, family connections, institutional prestige, and relationships with powerful scholars. For generations,

Yet his essays can provide precisely that opportunity: A Black person said this. Tyler becomes the last Black person they talked to, and his arguments enter the public curriculum carrying an authority.
So every time someone sends me one of Tyler's essays as though his "Blackness" settles an argument about DEI, affirmative action, or the qualifications of Black faculty, the same ritual is happening again. Tyler Austin Harper

1103

Michael D. Green, PhD @michaeldgreen.phd · 22/08/2026

Seems like a program favoring underrepresented views to me. I was told DEI is unfair and the main thing wrong with universities. I’m sure those people who claim that will come out strongly against this in favor of more “meritocracy”

GSIDI is co-sponsored by Johns Hopkins University and the American Enterprise Institute. The aim of the initiative is to help broaden intellectual pluralism on college and university campuses by attending to the pipelines that eventually produce future university faculty. GSIDI seeks to advance this mission by identifying and assisting prospective graduate students who are dedicated to pluralistic inquiry, and especially those interested in questions, hypotheses or approaches that may be labeled conservative, moderate or heterodox liberal.

34912

Michael D. Green, PhD @michaeldgreen.phd · 20/08/2026

Came out of my summer (personal) writing hiatus to talk about the hypothetical world where “AI cures all disease”. As we know well, a lot of “cures” ≠ care www.notbeinggreen.com/p/curing-all...

In healthcare we judge people by improved health outcomes. We know about United States healthcare being troubled. Hypothetically curing disease is not the same as providing services for people who desperately need them. Orchestrating care and making recommendations to people who are losing access will also create a frustrating circumstance. People already do not like AI companies because they see the companies building infrastructure in their neighborhoods, they feel the cost of electricity rising, the technology has allowed people to overwhelm every corner of the internet that is based in text generation, it makes it easier for their loved ones to fall victim to scams, and many of the prominent figures mention how it might cause wide scale job disruption. How are people going to have all their diseases cured if the administration that many of the prominent Al companies monetarily support is cutting back on healthcare access, and hypothesized job displacement could push people from stable jobs?

Patients could plausibly get great clinical information from Al, get better treatment from a physician using new Al tools, but then their lack of access and resources could prevent them from managing their healthcare needs. This is the dilemma people in my family faced when they had the loving support of my mother who could explain their disease prognosis, carefully explain to them what they could do, and be their care advocate, yet did not have the resources to seek care. These are people who are still failed by the system even with new cures that might come someday. System building will be the hardest step of the improvement in healthcare Al companies need. They need to learn lessons from those of us who hear about people who had great information and doctors who cared, but still lacked the resources to execute.

196

Michael D. Green, PhD @michaeldgreen.phd · 19/08/2026

Katalin Karikó and Drew Weissman 20+ years ago:

Mark Cuban: “Tell me where Claude I got this wrong”

040

Michael D. Green, PhD @michaeldgreen.phd · 17/08/2026

Chairs and Deans minutes before the meeting where they deny a promising young faculty member tenure

010

Michael D. Green, PhD @michaeldgreen.phd · 14/08/2026

Absolutely not. @iwashyna.bsky.social used the word philanthropy here. I think that the more common way I’ve seen this phenomenon described is “sponsorship” or “mentorship”. While I don’t think this is the same as relying on a private foundation, it is still charity.

We need urgent action by a new class of' philanthropists to save the young scientists who are the most vulnerable and the most innovative part of our system of discovery. My proposal is that healthcare professionals at the height of their career can and should engage in moderate-scale philanthropy to save and promote young careers - and thereby save the lives of patients who will benefit from their discoveries. Doing this will require rapid adoption of new skills from young scientists, old institutions, and new professionals stepping into a patron role.

100

Michael D. Green, PhD @michaeldgreen.phd · 14/08/2026

Really liked this essay from @iwashyna.bsky.social While I am skeptical that philanthropy desires to replace the scale of the losses (and harms) of the future leaders of medical research, they certainly can stopgap before we are “insolvent.” voices.nejm.org/doi/full/10....

241

Michael D. Green, PhD @michaeldgreen.phd · 06/08/2026

Dr. Cohen had already renegotiated their grant once. How can you work with someone whose claims about a desire to support science are empty words or outright contradictory? Does the trust of the communities targeted in this project not matter?

Cohen is especially frustrated because in December 2025 she and the NIH program officer who oversees her grant had renegotiated it to align with Bhattacharya's priorities-yet the changes never appeared in the grant abstract. "I am honestly so angry I can't think straight," says Cohen, also speaking in her personal capacity.

Cohen adds that the terminations "fly in the face" of a federal law requiring that NIH-funded Alzheimer's research study health disparities. Terminating them will waste millions of dollars already invested in the work and lead to layoffs of dozens of staff, she says. Her group had spent $5.2 million of an expected $9.6 million.
Both teams had worked for years to build trust with the Pittsburgh community, she and Dubowitz add. That makes the termination
"really infuriating and heartbreaking," Cohen

140

Michael D. Green, PhD @michaeldgreen.phd · 04/08/2026

Y’all need to get with the times, we don’t communicate like THIS anymore!

111

Michael D. Green, PhD @michaeldgreen.phd · 29/07/2026

At the end of the day academia is still a job. We are putting up with a lot more BS b/c of political intereference. Not great!

MONEY CAN BE EXCHANGED FOR GOODS AND SERVICES.

031

Michael D. Green, PhD @michaeldgreen.phd · 29/07/2026

@drugmonkey.bsky.social raising some important points here! If salaries aren’t increasing with inflation, or budgets, or the scope of what we can do with that money, or service requirements to be promoted. What do we expect our culture to look like…

If we adjust the $180,100 cap from 2005 forward, the inflation calculator says it should be $307,173 in 2026, i.e., 35% higher. If we index to the ten percent reduction from 2012, that $179,700 should be $257,860, or 14% higher.
Dream on.
There will be no major adjustments to account for this grinding erosion of salaries caused by inflation. All we can do as individuals is work our way up the traditional ranks. Take our annual increases that do not actually keep up with inflation. Reach our promotion steps of Associate and Full Professor. Use the internal mechanisms to accelerate ahead on the local compensation plans.
Take on new responsibilities in, gasp, administration. Pull off a retention package ploy.

132

Michael D. Green, PhD @michaeldgreen.phd · 26/07/2026

5th year undergrad reunion photo dump.

040

Michael D. Green, PhD @michaeldgreen.phd · 23/07/2026

Good thing all the responses are “not medical advice” 🫩🫩🫩.

OpenAl is rolling out ChatGPT Health to everyone in the US on Thursday, allowing more people to connect their medical records and health-tracking information to the chatbot. During a briefing, Ashley Alexander, OpenAl's vice president of health product, says the company's models
"are now capable of reasoning at levels that are better than clinician level."

340

Michael D. Green, PhD @michaeldgreen.phd · 11/07/2026

I am still an east coast supremicist, but I do think it’s pretty cool y’all have caves with wine in them out West.

010

Michael D. Green, PhD @michaeldgreen.phd · 11/07/2026

How you were navigating Palo Alto

010

Michael D. Green, PhD @michaeldgreen.phd · 09/07/2026

Running a lab is like running a small business. When you run out of money, you close. Right now we are favoring incumbents and squeezing out the most vulnerable. Life saving research is abruptly shutting down and early career scientists are paying the price!

0176

Michael D. Green, PhD @michaeldgreen.phd · 08/07/2026

The message here about disincentiving research is a good one. Also think it should be applied to TODAY, not just if proposed OMB rules go into effect. Many people were harmed (even when they won in court) and the “wins” aren’t proportional to the harms. Great reporting by @aniloza.bsky.social

The OMB rule, which the American
Association for the Advancement of Science
referred to as a "brazen power grab" has attracted attention from Congress. Sen.
Susan Collins (R-Maine), the head of the appropriations committee, asked for an extension of the comment period for the proposal and warned that it could
"disincentivize scientific researchers and institutions from seeking the federal financial assistance they need to participate in multiyear, lifesaving trials." In a hearing with Vought, Rep. Rosa DeLauro (D-Conn.) accused him of "putting all of these grants through a political lens and someone's political ideology, adding, "It's wrong and we're not going to let it happen."

11615

Michael D. Green, PhD @michaeldgreen.phd · 06/07/2026

Really liked this anecdote. There’s a lot of worry about people cheating the scientific process with AI (getting ahead with excessive outputs, productivity theater, etc.) Honestly you shouldn’t be moved by science that’s based on pure speed or volume. Creativity matters! @matthewherper.bsky.social

In an interview, she explained further:
"What if when I let the model read all the literature, not just the lab data of a couple of screens, then its ability to predict what would actually be impacted in cells is huge, but it's all the stuff I already know. It's not the stuff that is interesting" She compared it to an AI tool writing email responses in a boring way - but noted that in science,
"boring is particularly bad."

263

Michael D. Green, PhD @michaeldgreen.phd · 03/07/2026

Lots of striking stuff in here. This really got me. If you can’t get your candidates across the finish line in primaries AND you can’t raise money, what do you have?

2125

Michael D. Green, PhD @michaeldgreen.phd · 01/07/2026

Man this is terrible. Again how do we proceed when this is the reality for many? www.medscape.com/viewarticle/...

Effectively Unfundable
Aaron Scherer, PhD, associate professor of internal medicine at the University of lowa's Carver School of Medicine, studies why people do or don't get vaccinated. On April 1, 2025, his career-development award — which covered most of his salary — was abruptly terminated. The reason he was given, he said, was that 'it is the policy of NIH not to prioritize vaccine hesitancy." With vaccine-preventable diseases resurging, he said, the decision made no sense.
The fallout reshaped his career. His project manager left; his department had to absorb his and his graduate student's salaries. Because his planned next grant was also on vaccine confidence
— now effectively unfundable — the award meant to launch his independence instead left him starting over. He has since submitted three proposals on unrelated topics; the earliest, he said, might be funded in April 2027, if at all.
. "95% of my salary is
supposed to come from grant funding,'
" he said.

16665243

Michael D. Green, PhD @michaeldgreen.phd · 30/06/2026

Watching the live webinar that accompanied the announcement of this product between @matthewherper.bsky.social , Lotte Knudson, and Dario Amodei. Lots of interesting anecdotes so far!

020

Michael D. Green, PhD @michaeldgreen.phd · 30/06/2026

There are lots of takes on the capabilities (and limits) at the intersection of AI and science. I share skepticism that these companies have a long-term goal of replacing our work. Especially companies that are only thousands of people, changing tasks feels a lot more likely than replacement.

At the same time, while Gosalvez thinks AI could disrupt the field in the short term, he's not afraid in the long term. In his view, people who try to "vibe-code" their own electronic lab notebooks will quickly realize there's more to a functional enterprise
product than just the code - including making sure the product meets security and validation checks, as well as product improvements. He's not sure that the large foundation models want to get into the
application layer in the long term, either.

130

Michael D. Green, PhD @michaeldgreen.phd · 30/06/2026

Need LeBron to end his career the right way and come join my Washington Wizards

010

Michael D. Green, PhD @michaeldgreen.phd · 27/06/2026

I’m going the other route, good luck!

Meme talking about the only way to get a
Grant these days

020

Michael D. Green, PhD @michaeldgreen.phd · 27/06/2026

HHS: “We want more gold-standard science!” Also, HHS: *long political review that delays funding and halts life-saving new discoveries if you mention a “recruitment plan” in your grant proposal*

A bunch of words that usually signals thoughtful science, I highlighted “recruitment plan”, which is necessary for conducting any clinical trial…

616767

Michael D. Green, PhD @michaeldgreen.phd · 26/06/2026

There’s now a parent F99/K00 opportunity (YAY). On LinkedIn it looks like NCI is the only institute advertising it on an official NIH account. Juxtapose this w/ where I got my award (NIA) which sunset their ENTIRE Institute LI page 3 months ago… Shouldn’t all institutes get to communicate…

243